Literature DB >> 24005838

Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients.

Francesco Ursini1, Alessandro Grembiale, Saverio Naty, Rosa Daniela Grembiale.   

Abstract

The objective of this cross-sectional study is to investigate the relationship between inflammatory markers (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, and complement C3) and insulin resistance (estimated with the surrogate measure homeostasis model assessment of insulin resistance (HOMA-IR)) in Psoriatic arthritis (PsA) patients. Sixty-seven patients with PsA and 138 age- and sex-matched controls were recruited from the Rheumatology Outpatient Clinic of the University of Catanzaro, Catanzaro (Italy). Plasma glucose, insulin, triglycerides, total cholesterol, LDL cholesterol, and high-density lipoprotein (HDL) cholesterol were measured after at least 12-h fasting. CRP was measured by a high-sensitivity turbidimetric immunoassay. ESR was measured by capillary photometry. Serum C3 and C4 were measured by nephelometry. Insulin resistance was estimated using the original HOMA as reported by Matthews et al. (Diabetologia 28(7):412-419, 1985) from overnight fasting insulin and glucose values, with the following formula: HOMA-IR = glucose (in milligrams per deciliter) × insulin (in micro units per milliliter)/405. Patients and controls had similar body mass index (BMI), blood pressure, and fasting glucose, but fasting serum insulin was higher in PsA patients (median (interquartile range (IQR)) 12.96 (6.35-24.65) for PsA and 10.37 (6.97-15.11) for controls; p = 0.005). Consequently, also the surrogate measure of insulin resistance HOMA-IR was significantly higher in patients (median (IQR) 3.77 (1.58-5.18) for PsA and 2.33 (1.67-3.62) for controls; p = 0.008). In univariate analysis, ln(HOMA-IR) correlated positively with BMI, systolic blood pressure (sBP), dBP, ln(TG), WBC, ln(ESR), ln(CRP) and C3, while correlated negatively with total and HDL cholesterol. In multiple linear regression analysis including age, sex and BMI, serum C3 reached the higher standardized β coefficient, while among other variables only ln(ESR) maintained a weak correlation with ln(HOMA-IR) when sBP was added to the model. When all variables were inserted in a single model, only C3 was independently correlated with ln(HOMA-IR). In a stepwise multiple regression model, serum C3 was selected as the strongest single contributing variable. The model explained 61 % of the variance in ln(HOMA-IR) (R (2) = 0.61). Insulin resistance, estimated with the surrogate measure HOMA-IR, is higher in PsA patients compared to age- and sex-matched controls. Serum C3 could represent a simple marker of insulin resistance in psoriatic arthritis patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24005838     DOI: 10.1007/s10067-013-2366-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  43 in total

1.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

2.  Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006.

Authors:  Thorvardur Jon Love; Abrar A Qureshi; Elizabeth Wood Karlson; Joel M Gelfand; Hyon K Choi
Journal:  Arch Dermatol       Date:  2010-12-20

3.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.

Authors:  D M van der Heijde; M A van't Hof; P L van Riel; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

4.  Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin.

Authors:  V Van Harmelen; S Reynisdottir; K Cianflone; E Degerman; J Hoffstedt; K Nilsell; A Sniderman; P Arner
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

Review 5.  Mortality and causes of death in psoriatic arthritis.

Authors:  Ramani Arumugam; Neil J McHugh
Journal:  J Rheumatol Suppl       Date:  2012-07

6.  Psoriasis alters HDL composition and cholesterol efflux capacity.

Authors:  Michael Holzer; Peter Wolf; Sanja Curcic; Ruth Birner-Gruenberger; Wolfgang Weger; Martin Inzinger; Dalia El-Gamal; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Lipid Res       Date:  2012-05-30       Impact factor: 5.922

7.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

8.  Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.

Authors:  Esperanza Martínez-Abundis; Claudia Reynoso-von Drateln; Eduardo Hernández-Salazar; Manuel González-Ortiz
Journal:  Arch Dermatol Res       Date:  2007-08-28       Impact factor: 3.017

9.  The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis.

Authors:  A Baldo; A D Sniderman; S St-Luce; R K Avramoglu; M Maslowska; B Hoang; J C Monge; A Bell; S Mulay; K Cianflone
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

Review 10.  Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives.

Authors:  Wolf-Henning Boehncke; Sandra Boehncke
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

View more
  12 in total

1.  H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome.

Authors:  P Ruscitti; P Cipriani; P Di Benedetto; V Liakouli; O Berardicurti; F Carubbi; F Ciccia; G Guggino; G Triolo; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

2.  Complement C3 Is the Strongest Predictor of Whole-Body Insulin Sensitivity in Psoriatic Arthritis.

Authors:  Francesco Ursini; Salvatore D'Angelo; Emilio Russo; Kassandra Nicolosi; Antonio Gallucci; Agostino Chiaravalloti; Caterina Bruno; Saverio Naty; Giovambattista De Sarro; Ignazio Olivieri; Rosa Daniela Grembiale
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

3.  Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study.

Authors:  Piero Ruscitti; Francesco Ursini; Paola Cipriani; Francesco Ciccia; Vasiliki Liakouli; Francesco Carubbi; Giuliana Guggino; Onorina Berardicurti; Rosadaniela Grembiale; Giovanni Triolo; Giovambattista De Sarro; Roberto Giacomelli
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Francesco Ursini; Christian Leporini; Fabiola Bene; Salvatore D'Angelo; Daniele Mauro; Emilio Russo; Giovambattista De Sarro; Ignazio Olivieri; Costantino Pitzalis; Myles Lewis; Rosa Daniela Grembiale
Journal:  Sci Rep       Date:  2017-07-13       Impact factor: 4.379

5.  Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study.

Authors:  Piero Ruscitti; Francesco Ursini; Paola Cipriani; Vasiliki Liakouli; Francesco Carubbi; Onorina Berardicurti; Giovambattista De Sarro; Roberto Giacomelli
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

Review 6.  Current treatment options for psoriatic arthritis: spotlight on abatacept.

Authors:  Francesco Ursini; Emilio Russo; Roberto De Giorgio; Giovambattista De Sarro; Salvatore D'Angelo
Journal:  Ther Clin Risk Manag       Date:  2018-06-06       Impact factor: 2.423

Review 7.  Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis.

Authors:  Rosario Peluso; Francesco Caso; Marco Tasso; Vincenzo Sabbatino; Roberta Lupoli; Matteo Nicola Dario Di Minno; Francesco Ursini; Luisa Costa; Raffaele Scarpa
Journal:  Open Access Rheumatol       Date:  2019-06-28

8.  Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis.

Authors:  Iván Arias de la Rosa; Pilar Font; Alejandro Escudero-Contreras; María Dolores López-Montilla; Carlos Pérez-Sánchez; María Carmen Ábalos-Aguilera; Lourdes Ladehesa-Pineda; Alejandro Ibáñez-Costa; Carmen Torres-Granados; Yolanda Jimenez-Gomez; Alejandra Patiño-Trives; María Luque-Tévar; María Carmen Castro-Villegas; Jerusalem Calvo-Gutiérrez; Rafaela Ortega-Castro; Chary López-Pedrera; Eduardo Collantes-Estévez; Nuria Barbarroja
Journal:  Ther Adv Chronic Dis       Date:  2020-10-21       Impact factor: 5.091

9.  MALDI-TOF MS Characterisation of the Serum Proteomic Profile in Insulin-Resistant Normal-Weight Individuals.

Authors:  Katarzyna Pastusiak; Eliza Matuszewska; Dagmara Pietkiewicz; Jan Matysiak; Pawel Bogdanski
Journal:  Nutrients       Date:  2021-10-28       Impact factor: 5.717

10.  Association between complement C3 and the prevalence of metabolic-associated fatty liver disease in a Chinese population: a cross-sectional study.

Authors:  Limin Feng; Ying Zhao; Wei-Lin Wang
Journal:  BMJ Open       Date:  2021-10-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.